m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03819)
Name
IT-139
Status
Phase 1
TTD Drug ID
D0Q4LG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Endoplasmic reticulum chaperone BiP (HSPA5)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for IT-139. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IT-139 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for IT-139. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of IT-139 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). [1], [2]
References
Ref 1 METTL3 mediates osteoblast apoptosis by regulating endoplasmic reticulum stress during LPS-induced inflammation. Cell Signal. 2022 Jul;95:110335. doi: 10.1016/j.cellsig.2022.110335. Epub 2022 Apr 21.
Ref 2 A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86. doi: 10.1038/labinvest.2008.2. Epub 2008 Feb 11.